Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022762621> ?p ?o ?g. }
- W2022762621 endingPage "606" @default.
- W2022762621 startingPage "597" @default.
- W2022762621 abstract "Drugs currently used for patients with Parkinson's disease provide temporary relief of symptoms but do not halt or slow the underlying neurodegenerative disease process. Increasing evidence suggests that neurons die in Parkinson's disease by a process called apoptosis, which may be triggered by mitochondrial impairment and oxidative stress. We report that two novel synthetic inhibitors of the tumor suppressor protein p53, pifithrin-alpha (PFT-alpha) and Z-1-117, are highly effective in protecting midbrain dopaminergic neurons and improving behavioral outcome in a mouse model of Parkinson's disease. Mice given intraperitoneal injections of PFT-alpha or Z-1-117 exhibited improved motor function, reduced damage to nigrostriatal dopaminergic neurons and reduced depletion of dopamine and its metabolites after exposure to the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP caused an increase in the level of the proapoptotic protein Bax, which was prevented by giving mice PFT-alpha and Z-1-117. PFT-alpha and Z-1-117 also suppressed Bax production and apoptosis in cultured dopaminergic cells exposed to MPP(+). Our findings demonstrate a pivotal role for p53 in experimental parkinsonism and identify a novel class of synthetic p53 inhibitors with clinical potential." @default.
- W2022762621 created "2016-06-24" @default.
- W2022762621 creator A5003062113 @default.
- W2022762621 creator A5006888475 @default.
- W2022762621 creator A5017444330 @default.
- W2022762621 creator A5025381905 @default.
- W2022762621 creator A5032350732 @default.
- W2022762621 creator A5043772835 @default.
- W2022762621 creator A5056649584 @default.
- W2022762621 creator A5058145741 @default.
- W2022762621 creator A5068354292 @default.
- W2022762621 creator A5083040475 @default.
- W2022762621 date "2002-10-24" @default.
- W2022762621 modified "2023-10-10" @default.
- W2022762621 title "p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism" @default.
- W2022762621 cites W1504584187 @default.
- W2022762621 cites W1513688899 @default.
- W2022762621 cites W1535426243 @default.
- W2022762621 cites W1877873625 @default.
- W2022762621 cites W1900066504 @default.
- W2022762621 cites W1908458283 @default.
- W2022762621 cites W1920883260 @default.
- W2022762621 cites W1964230438 @default.
- W2022762621 cites W1965575645 @default.
- W2022762621 cites W1967880683 @default.
- W2022762621 cites W1968054339 @default.
- W2022762621 cites W1969455851 @default.
- W2022762621 cites W1977888667 @default.
- W2022762621 cites W1986188355 @default.
- W2022762621 cites W1987255258 @default.
- W2022762621 cites W1989149919 @default.
- W2022762621 cites W1989350751 @default.
- W2022762621 cites W1991486160 @default.
- W2022762621 cites W1991555457 @default.
- W2022762621 cites W1994548914 @default.
- W2022762621 cites W2004698905 @default.
- W2022762621 cites W2007822968 @default.
- W2022762621 cites W2008254819 @default.
- W2022762621 cites W2020834781 @default.
- W2022762621 cites W2043075342 @default.
- W2022762621 cites W2047254990 @default.
- W2022762621 cites W2049359499 @default.
- W2022762621 cites W2060449537 @default.
- W2022762621 cites W2060618478 @default.
- W2022762621 cites W2061362388 @default.
- W2022762621 cites W2068829557 @default.
- W2022762621 cites W2072942020 @default.
- W2022762621 cites W2072998862 @default.
- W2022762621 cites W2077561395 @default.
- W2022762621 cites W2084959937 @default.
- W2022762621 cites W2104912043 @default.
- W2022762621 cites W2115640450 @default.
- W2022762621 cites W2141487162 @default.
- W2022762621 cites W2149959669 @default.
- W2022762621 cites W2150656456 @default.
- W2022762621 cites W2150881749 @default.
- W2022762621 cites W2155255686 @default.
- W2022762621 cites W2171030272 @default.
- W2022762621 cites W2281194714 @default.
- W2022762621 cites W4210995338 @default.
- W2022762621 cites W4230210723 @default.
- W2022762621 cites W4246806002 @default.
- W2022762621 cites W4250389091 @default.
- W2022762621 cites W4361773848 @default.
- W2022762621 doi "https://doi.org/10.1002/ana.10350" @default.
- W2022762621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12402257" @default.
- W2022762621 hasPublicationYear "2002" @default.
- W2022762621 type Work @default.
- W2022762621 sameAs 2022762621 @default.
- W2022762621 citedByCount "198" @default.
- W2022762621 countsByYear W20227626212012 @default.
- W2022762621 countsByYear W20227626212013 @default.
- W2022762621 countsByYear W20227626212014 @default.
- W2022762621 countsByYear W20227626212015 @default.
- W2022762621 countsByYear W20227626212016 @default.
- W2022762621 countsByYear W20227626212017 @default.
- W2022762621 countsByYear W20227626212018 @default.
- W2022762621 countsByYear W20227626212019 @default.
- W2022762621 countsByYear W20227626212020 @default.
- W2022762621 countsByYear W20227626212021 @default.
- W2022762621 countsByYear W20227626212022 @default.
- W2022762621 countsByYear W20227626212023 @default.
- W2022762621 crossrefType "journal-article" @default.
- W2022762621 hasAuthorship W2022762621A5003062113 @default.
- W2022762621 hasAuthorship W2022762621A5006888475 @default.
- W2022762621 hasAuthorship W2022762621A5017444330 @default.
- W2022762621 hasAuthorship W2022762621A5025381905 @default.
- W2022762621 hasAuthorship W2022762621A5032350732 @default.
- W2022762621 hasAuthorship W2022762621A5043772835 @default.
- W2022762621 hasAuthorship W2022762621A5056649584 @default.
- W2022762621 hasAuthorship W2022762621A5058145741 @default.
- W2022762621 hasAuthorship W2022762621A5068354292 @default.
- W2022762621 hasAuthorship W2022762621A5083040475 @default.
- W2022762621 hasConcept C126322002 @default.
- W2022762621 hasConcept C134018914 @default.
- W2022762621 hasConcept C137183658 @default.
- W2022762621 hasConcept C169760540 @default.
- W2022762621 hasConcept C185592680 @default.